the serum CEA (3.30 vs. 2.06 ng/mL, P<0.001), CA724 (2.43 vs. 1.82 U/mL, P=0.015), NSE (17.11 vs. 13.02 ng/mL, P<0.001), CYFRA21 (4.82 vs. 3.18 ng/mL, P<0.001), and CA242 (6.50 vs. 4.10 U/mL, P=0.024) levels in the CADM group were significantly higher than those in the CDM group. This evidence concerns the gene CEACAM5 and clinically amyopathic dermatomyositis.